Skip to content
‹ Back to IndustriesSciences

FDA SHIFTS TO CFU LABELING FOR SUPPLEMENTS, STILL COMES UP SHORT ACCORDING TO EXPERTS

In September 2018, the FDA issued a draft guidance on how to label supplements containing live microbials. The announcement presents the organization’s “intent to exercise enforcement discretion to allow supplement companies to use colony forming units (CFUs) when declaring the quantity of live microbials on a Supplement Facts Label.”  Why the Guidance Was Issued The new guidance…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · · Promoted Content
Share
FDA SHIFTS TO CFU LABELING FOR SUPPLEMENTS, STILL COMES UP SHORT ACCORDING TO EXPERTS

Key takeaways

01

In September 2018, the FDA issued a draft guidance on how to label supplements containing live microbials.

02

The announcement presents the organization’s “intent to exercise enforcement discretion to allow supplement companies to use colony forming units (CFUs) when declaring the quantity of live microbials on a Supplement Facts Label.”  Why the Guidance Was Issued The new guidance…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In September 2018, the FDA issued a draft guidance on how to label supplements containing live microbials. The announcement presents the organization’s “intent to exercise enforcement discretion to allow supplement companies to use colony forming units (CFUs) when declaring the quantity of live microbials on a Supplement Facts Label.”

 Why the Guidance Was Issued

The new guidance comes in response to a widespread disagreement over the use of the weight of ingredients versus colony forming units (CFUs). The new guidance does allow manufacturers to incorporate CFUs; however, weight must still be included on the label, and listed in order of predominance by mass quantity.

Despite the fact that the FDA believes “CFUs provide a useful description of the quantity of live microbial dietary ingredients,” it rejected a petition from the International Probiotics Association to list ingredients only by CFUs rather than weight. While disappointed that the FDA denied the petition, the IPA still considers the new guidance a victory in promoting the use of CFUs. Although weight, which has proven to be an inaccurate way to measure microbials, will continue to be a requirement, the addition of CFUs in live microbial labeling provides consumers with more information to choose the best product for them.

FDA Will Allow CFU Labeling, But Supplements Must Meet 7 Requirements

 The FDA will permit CFU labeling of microbial dietary ingredients provided the following requirements are met:

  1. The quantity is first listed in terms of weight.
  2. The declaration of quantity in CFUs is expressed in a manner that is clearly separate and readily distinguishable from the weight, e.g., as a parenthetical or in a subset line.
  3. The declaration of the quantity in CFUs is formatted in clear terms that can easily be understood by a common reader, e.g., 10 billion or 300* (where the unit that “*” is intended to represent is a typical measurement of CFUs, and is clearly indicated elsewhere in the Supplement Facts label).
  4. The declaration of quantity in CFUs is accurate and not misleading, does not render misleading other aspects of the Supplement Facts label, or other aspects of the product label.
  5. The declaration of quantity in CFUs measures only live microbial ingredients and does not include inactive, dead, or nonviable organisms.
  6. Live microbial dietary ingredients in a proprietary blend are listed in descending order of predominance by weight; and
  7. The product label otherwise complies with all applicable laws and regulations.

 Scientists Prefer CFUs to Measure Live Microbials

CFUs are the scientifically accepted unit of measurement for probiotics. Rather than painstakingly counting every cell individually under a microscope, scientists dilute a sample of microbes and spread it across a Petri plate, allowing them to count groups of microbes, called colonies, with the naked eye. However, each CFU doesn’t necessarily correspond to a single microbe. But if the cells stick together in lumps or chains, the CFU instead refers to these groupings. Each colony is assumed to have grown from a single colony-forming unit, or CFU.

 CRN Commends Guidance but Has Reservations

Another group advocating for CFU usage is the Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement and functional food industry. While the news of the draft guidance was indeed hopeful, they worry it doesn’t go far enough. Like the IPA, CRN’s main concern is that weight, which must still be included in labeling, isn’t an accurate measurement for determining live microbial counts in products.

CRN thinks the FDA is heading in the right direction but cautions that a “dual listing of ingredient quantity in weight and CFUs presents conflicting product labeling information and puts responsible industry members in an untenable position.”

Why This Matters to Supplement Companies

 At present, the FDA is garnering much feedback on their draft guidance, opinions which may alter their current stance that weight must be included in supplement labeling. Deerland Probiotics & Enzymes wants to ensure that the industry stays abreast of regulatory changes. By subscribing to our blog, Digestible, you can remain current with market trends and regulatory developments that affect how the supplements you sell must be labeled, and the best way to communicate any changes with your customers.

Lear more at deerlandenzymes.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

PC
Promoted Content
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512